A Study of Intravenous Aflibercept With Docetaxel in Chinese Patients With Solid Tumors
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
- To confirm the dose of aflibercept in western studies by assessing the dose-limiting
toxicity (DLT) of intravenous (IV) aflibercept when administered in combination with
docetaxel given intravenously every 3 weeks in Chinese patients with solid tumors.
Secondary Objectives:
- To assess the safety profile of intravenous (IV) aflibercept when administered in
combination with docetaxel
- To determine the pharmacokinetics of IV aflibercept and docetaxel when administered in
combination
- To make a preliminary assessment of antitumor effects of the combination of docetaxel
plus aflibercept in patients with evaluable disease
- To evaluate the immunogenicity of IV aflibercept
- To measure endogenous free Vascular Endothelial Growth Factor (VEGF)